Vaxcyte, Inc. (PCVX) 8-K Current Report: February 24, 2026
Filed: February 24, 2026
Health Care
Biological Products, (No Diagnostic Substances)Vaxcyte, Inc. (PCVX) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Vaxcyte, Inc. 8-K Feb 24, 2026 Event Analysis
Item 8.01 · Other Events
- • New ATM offering established Feb 24, 2026 — up to $500M in common stock via Leerink Partners, replacing prior Jefferies facility
- • Placement agent fee up to 3.00% of gross proceeds — dilution cost to existing shareholders on any shares sold
- • Prior Jefferies ATM (est. 2021) terminated after ~$270.3M raised — new facility resets capacity with a new counterparty
- • No obligation to sell any shares — actual timing, price, and volume at company's discretion; no guaranteed capital raise
- • Pre-clinical biotech using ATM for runway extension — watch for cadence of share sales as signal of cash burn vs. pipeline milestones
Other Vaxcyte, Inc. 8-K Filings
Get deeper insights on Vaxcyte, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.